News

LISAvienna News

LISA VR lecture at Open Days 2007 in Brussels

From October 8 to 11 2007 the 5th OPEN DAYS European Week of Regions and Cities took place in Brussels. About 5,000...

Thomas Jenuwein receives the Erwin Schrödinger Prize of the Austrian Academy of Sciences

Prof. Dr. Thomas Jenuwein receives the Erwin Schrödinger Prize in honour of his outstanding contributions to molecular...

Kirsten Peter Rabitsch Award 2007

Ralph Neumüller from the team of Jürgen Knoblich (IMBA) is this year's winner of the Kirsten Peter Rabitsch Award. The...

Umbrella brand Life Science Austria launched

On October 2, 2007 the new Austrian umbrella brand “Life Science Austria” has been introduced to the media. The umbrella...

Improved business in life sciences lecture program starts 2007

Starting with the winter term 2007 the business in life sciences lecture program at the University of Vienna’s Molecular...

Intercell: Announcement of Novartis' share in voting rights

Following the completion of a capital increase of 4.8 million shares, which were sold to Novartis Pharma AG at an issue...

Austrianova establishes Singapore subsidiary

Austrianova establishes Singapore subsidiary: New facility located in Biopolis, Singapore’s high tech biomedical...

Antibody Engineering Company f-star raises EUR 6 million in Series A Financing Round

Antibody Engineering Company F-Star Raises EUR 6.0 million in Series A Financing from Aescap Venture and Atlas Venture

Ablynx and Boehringer Ingelheim announce major global strategic alliance to discover, develop and commercia...

Ablynx and Boehringer Ingelheim announce major global strategic alliance to discover, develop and commercialise novel...

Sanochemia: US-Partner Avigen commences multicentric phase II study in the development programme for tolper...

Sanochemia: US-Partner Avigen commences multicentric phase II study in the development programme for tolperisone

Boehringer Ingelheim to initiate first Phase III pivotal study for new oncology compound BIBW 2982

Boehringer Ingelheim announced today from the 12th World Conference on Lung Cancer (WCLC) that the company plans to...

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.